Pricing Log in Create free account

BioLineRx Ltd. (BLRX) vs Tempest Therapeutics, Inc. (TPST)

BioLineRx Ltd. and Tempest Therapeutics, Inc. are both Biotechnology companies. BioLineRx Ltd. and Tempest Therapeutics, Inc. are of similar size ($10.7M and $10.2M). Tempest Therapeutics, Inc. grew revenue faster over the last twelve months: −53.0% against −91.9%. Tempest Therapeutics, Inc. has the higher net margin (0.00% vs −502.1%) and the higher return on invested capital (0.00% vs −74.3%). Across the 16 metrics below, BioLineRx Ltd. leads on 9 and Tempest Therapeutics, Inc. on 7.

Valuation

Metric BLRX TPST Biotechnology median
P/E n/m n/m 8.50
P/S 6.51 29.13 9.71
P/B 0.55 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.93 33.65 9.21
Earnings yield (82.84%) (690.32%) (33.15%)
Free cash flow yield (119.61%) (224.23%) (25.50%)

Profitability

Metric BLRX TPST Biotechnology median
Gross margin 80.03% 0.00% 65.16%
Operating margin (874.28%) 0.00% 0.00%
Net margin (502.08%) 0.00% 0.00%
Free cash flow margin (776.29%) 0.00% 0.00%
Return on equity (38.10%) (931.14%) (56.36%)
Return on assets (18.21%) (237.25%) (48.04%)
Return on invested capital (74.28%) 0.00% 0.00%

Growth

Metric BLRX TPST Biotechnology median
Revenue growth (TTM) (91.93%) (52.98%) 6.02%
EPS growth (last fiscal year) 93.72% 67.55% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BLRX TPST Biotechnology median
Debt to equity 0.40 0.00 0.00
Current ratio 1.20 0.38 4.72
Net debt to EBITDA 1.22 0.29 0.96

Dividend

Metric BLRX TPST Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BLRX TPST Biotechnology median
Market cap 10.21m 10.73m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack